<!doctype html><html><head><meta charset=utf-8><title>MS relapse rate reduced 14 percent for each 4 ng increase in vitamin D</title>
<link rel=stylesheet href="/css/main.css?v=1753303881"><link rel=stylesheet href="/css/pagination.css?v=1753303881"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css><script src="/js/search-suggestions.js?v=1753303881"></script><script src="/js/search.js?v=1753303881"></script><script type=module>
        
        window.initPagefind = async function() {
            try {
                console.log('Loading Pagefind module...');
                window.pagefind = await import('/pagefind/pagefind.js');
                if (!window.pagefind) {
                    throw new Error('Failed to load Pagefind module - import returned empty result');
                }
                
                console.log('Initializing Pagefind...');
                const initResult = await window.pagefind.init();
                console.log('Pagefind loaded and initialized');
                
                
                if (window.searchInstance) {
                    console.log('Notifying Search instance of Pagefind initialization');
                    window.searchInstance.initializePagefind(window.pagefind);
                    console.log('Search instance successfully notified');
                } else {
                    console.warn('Search instance not found in global scope yet, but Pagefind is loaded');
                    
                }
            } catch (error) {
                console.error('CRITICAL ERROR: Failed to initialize Pagefind:', error);
                
                const errorDetails = error.stack || error.message || String(error);
                console.error('Error details:', errorDetails);
                
                
                const statusEl = document.querySelector('#search-status');
                const inputEl = document.querySelector('#search-input');
                
                if (statusEl) {
                    statusEl.textContent = 'Search unavailable: ' + error.message;
                    statusEl.style.display = 'block';
                    statusEl.style.color = 'red';
                }
                
                if (inputEl) {
                    inputEl.disabled = true;
                    inputEl.placeholder = 'Search unavailable';
                }
            }
        };
        
        
        window.pagefindInitialized = false;
        
        
        document.addEventListener('DOMContentLoaded', () => {
            console.log('DOM loaded, initializing Pagefind...');
            window.initPagefind();
        });
    </script></head><body><div class=top-nav><div class=home-icon><a href=/ title="Go to Home Page"><svg viewBox="0 0 576 512" width="28" height="28"><path d="M575.8 255.5c0 18-15 32.1-32 32.1h-32l.7 160.2c0 2.7-.2 5.4-.5 8.1V472c0 22.1-17.9 40-40 40H456c-1.1.0-2.2.0-3.3-.1-1.4.1-2.8.1-4.2.1H416 392c-22.1.0-40-17.9-40-40V448 384c0-17.7-14.3-32-32-32H256c-17.7.0-32 14.3-32 32v64 24c0 22.1-17.9 40-40 40H160 128.1c-1.5.0-3-.1-4.5-.2-1.2.1-2.4.2-3.6.2H104c-22.1.0-40-17.9-40-40V360c0-.9.0-1.9.1-2.8V287.6H32c-18 0-32-14-32-32.1.0-9 3-17 10-24L266.4 8c7-7 15-8 22-8s15 2 21 7L564.8 231.5c8 7 12 15 11 24z"/></svg></a></div><div class=search-container><div class=search-icon><i class="fas fa-search"></i></div><input type=text id=search-input placeholder=Search... disabled><div id=suggestions class=search-suggestions style=display:none></div><ul id=search-results style=display:none></ul><div id=search-results-panel class=search-results-panel><div class=results-header>Search Results</div><ul id=search-results-panel-list class=results-list></ul></div></div></div><div class=container><div class="content content-full-width" role=main><article><div class=scroll-nav-top><a href=javascript:void(0); id=scroll-to-bottom class=scroll-button aria-label="Scroll to bottom" onclick='return window.scrollTo({top:document.body.scrollHeight,behavior:"smooth"}),!1'><svg width="16" height="16" fill="currentcolor" viewBox="0 0 16 16"><path d="M8 4a.5.5.0 01.5.5v5.793l2.146-2.147a.5.5.0 01.708.708l-3 3a.5.5.0 01-.708.0l-3-3a.5.5.0 11.708-.708L7.5 10.293V4.5A.5.5.0 018 4z"/></svg>
<span>Scroll to Bottom</span></a></div><h1>MS relapse rate reduced 14 percent for each 4 ng increase in vitamin D</h1><time>May 18, 2012</time><div data-pagefind-body><h1 id=relationship-between-25-oh-d-serum-level-and-relapse-rate-in-multiple-sclerosis-patients>Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients</h1><h2 id=before-and-after-vitamin-d-supplementation>before and after vitamin D supplementation</h2><p>Therapeutic Advances in Neurological Disorders May 17, 2012 1756285612447090</p><p>Charles Pierrot-Deseilligny <a href=mailto:cp.deseilligny@psl.aphp.fr>cp.deseilligny@psl.aphp.fr</a></p><p>Service de Neurologie 1, Hôpital de la Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie (Paris VI), Paris, France</p><p>Sophie Rivaud-Péchoux: INSERM URMS 975, CNRS 7225, Université Pierre et Marie Curie (Paris VI), Paris, France</p><p>Pierre Clerson: Orgamétrie biostatistiques, Roubaix, France</p><p>Raphaël de Paz: Service de Neurologie 1, Hôpital de la Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie (Paris VI), Paris, France</p><p>Jean-Claude Souberbielle: Service d’explorations fonctionnelles, Hôpital Necker-Enfants-Malades, Assist. Publique- Hôpitaux de Paris, Université René Descartes (Paris V), Paris, France</p><p>Background: Vitamin D could play a protective role in multiple sclerosis.</p><p>Methods: In an observational, uncontrolled study, vitamin D3 supplementation ( <strong>3010 IU/day on average</strong> ) was given to 156 consecutive patients with relapsing–remitting multiple sclerosis, under first-line immunomodulatory therapy and with initial 25-OH-D serum level lower than 100 nmol/l (40 ng/ml). Relapses were determined for 29.1 ± 8.4 months during vitamin D and 29.8 ± 10.1 months before supplementation. The 25-OH-D level was measured before supplementation and several times during supplementation. The incidence rate of relapses before and during supplementation was estimated using negative binomial regression models with follow-up durations as offset terms. The incidence rate and incidence rate ratio of relapses at various 25-OH-D levels were also calculated using negative binomial regression models.</p><p>Results: In 76 patients, immunomodulatory therapy preceded vitamin D supplementation (by 4.2 ± 2.7 years) and in 80 patients both treatments were started simultaneously. Under supplementation, the 25-OH-D level increased from 49 ± 22 nmol/l to 110 ± 26 nmol/l on average. Pooling data collected before and during supplementation, we found a significant strong inverse relationship between the relapse incidence rate and the 25-OH-D level(p &lt; 0.0001), suggesting that vitamin D did indeed influence the relapse rate. Results of univariate, bivariate and multivariate analyses were analogous: in the multivariate model adjusted for age, disease duration and previous use of immunomodulatory therapy, every10 nmol increase in 25-OH-D level was associated with a reduction in the relapse incidence rate of 13.7%. Dividing iteratively the population made up of pooled periods into two subgroups according to the 25-OH-D levels, the relapse incidence rate ratio decreased as the 25-OH-D level increased up to 110 nmol/l, but a plateau effect was observed beyond this limit.</p><p>Conclusion: Further studies are warranted for accurate quantification of the vitamin D effect.</p><p><strong><span style=color:#00f>PDF is attached at the bottom of this page</span></strong></p><h2 id=figure-2--relapse-incidence-rate-according-to-25-oh-d-serum-level>Figure 2. Relapse incidence rate according to 25-OH-D serum level.</h2><img src=https://d378j1rmrlek7x.cloudfront.net/attachments/jpeg/ms-relapse-rate.jpg alt=image><p>X-axis: quintile of 25-OH-D serum levels;</p><p>Y-axis: incidence rate. Q1 to q5 are quintiles of 25-OH-D serum levels, numbers are relapse incidence rate:</p><p>q1 : ?55.5 nmol/l; q2: >55.5 to ?78.5 nmol/l; q3: >78.5 to ?97.25 nmol/l; q4: >97.25 to ?121.5 nmol/l; q5: >121.5 nmol/l.</p><p>In <strong>black</strong> , whole population;</p><p>in <strong><span style=color:#00f>blue</span></strong> , Group 1 (IMT started prior to vitamin D supplementation);</p><p>in <strong><span style=color:red>red</span></strong> , Group 2 (IMT started concomitantly with vitamin D supplementation).</p><p>– – – – – – – –</p><h2 id=summary>Summary</h2><ul><li><p>3100 IU reduced MS relapse rate</p></li><li><p>Each 4 nanogram increase in vitamin D level reduced relapse rate by 13.7 %</p></li><li><p>Started at 20 nanograms, Plateau at 44 nanograms</p></li><li><p>Chart appear to show that having IMT before Vitamin D hinders the amount of vitamin D increase</p></li></ul><h2 id=see-also-vitamindwiki>See also VitaminDWiki</h2><ul><li><p><a href=/posts/overview-ms-and-vitamin-d>Overview MS and vitamin D</a></p></li><li><p><a href=/posts/vitamin-d-reduces-multiple-sclerosis-relapses-but-not-with-interferon-treatment>Vitamin D reduces multiple sclerosis relapses, but not with interferon treatment – June 2012</a></p></li><li><p><a href="https://www.VitaminDWiki.com/tiki-browse_categories.php?parentId=18&amp;deep=on">All items in category MS and vitamin D</a> <strong><span style=color:#090>125 items as of May 2012</span></strong></p></li></ul><h2 id=see-also-web>See also web</h2><ul><li><a href=http://www.news-medical.net/news/20120620/Evidence-mounts-for-vitamin-D-multiple-sclerosis-role.aspx>Evidence mounts for vitamin D multiple sclerosis role</a> News Medical June 2012</li></ul><blockquote><p>doubling of vitamin D levels was associated with a 27% reduction in MS relapse risk.- Netherlands</p></blockquote><blockquote><p>10% reduction in rate of relapse for each 4 ng increase in vitamin D levels - Australia</p></blockquote><ul><li><a href=http://blog.vitamindcouncil.org/2012/07/12/study-vitamin-ds-effect-in-ms-may-be-larger-than-suspected/>Vitamin D Council comment on the paper</a></li></ul><blockquote><p>Overall, they saw a <strong>75% reduction in relapse rates</strong> if patients achieved a vitamin D level greater than 120 nmol/L (48 ng/ml).</p></blockquote><blockquote><p>Conclusion by author: “While awaiting the results of randomized controlled trials, which will not be available for several years, it appears <strong>wise to supplement all MS patients currently in a state of vitamin D insufficiency</strong> in order to bring their vitamin D levels to just over the 100 nmol/L (40 ng/ml) level, since such supplementation already seems unavoidable from a general medical view, is safe, and might also be neurologically beneficial for the course of the disease.”</p></blockquote></div><hr class=tag-separator><div class=tags><span>Tags: </span><a href=/tags/autoimmune.html><span class=tag>autoimmune</span></a>
<a href=/tags/blood-levels.html><span class=tag>blood levels</span></a>
<a href=/tags/dosage.html><span class=tag>dosage</span></a>
<a href=/tags/high-dose.html><span class=tag>high dose</span></a>
<a href=/tags/intervention.html><span class=tag>intervention</span></a>
<a href=/tags/multiple-sclerosis.html><span class=tag>multiple sclerosis</span></a>
<a href=/tags/multiple-sclerosis.html><span class=tag>Multiple Sclerosis</span></a>
<a href=/tags/therapeutic-intervention.html><span class=tag>therapeutic intervention</span></a>
<a href=/tags/vitamin-d.html><span class=tag>vitamin d</span></a></div><div data-pagefind-meta=tags hidden>autoimmune, blood levels, dosage, high dose, intervention, multiple sclerosis, Multiple Sclerosis, therapeutic intervention, vitamin d</div><div class=scroll-nav-bottom id=article-bottom><a href=javascript:void(0); id=scroll-to-top class=scroll-button aria-label="Scroll to top" onclick='return window.scrollTo({top:0,behavior:"smooth"}),!1'><svg width="16" height="16" fill="currentcolor" viewBox="0 0 16 16"><path d="M8 12a.5.5.0 00.5-.5V5.707l2.146 2.147a.5.5.0 00.708-.708l-3-3a.5.5.0 00-.708.0l-3 3a.5.5.0 10.708.708L7.5 5.707V11.5a.5.5.0 00.5.5z"/></svg>
<span>Back to Top</span></a></div></article></div></div><script src="/js/toc-sanitizer.js?v=1753303881"></script><script src="/js/tiki-redirects.js?v=1753303881"></script><script src="/js/lightspa.js?v=1753303881"></script><script>const spa=new LightSPA({mainContentSelector:'[role="main"]',navigationSelector:"[data-spa-nav]"});window.search=new Search({documentsUrl:"/search/search_documents.json.gz?v=1753303881",indexUrl:"/search/search_index.json.gz?v=1753303881"}),document.addEventListener("DOMContentLoaded",function(){function e(e){var t=e.querySelector(".category-expander"),n=e.querySelector(".subcategory-list");e.classList.contains("collapsed")?(e.classList.remove("collapsed"),e.classList.add("expanded"),t.textContent="-",n.style.display="block"):(e.classList.remove("expanded"),e.classList.add("collapsed"),t.textContent="+",n.style.display="none")}document.querySelectorAll(".category-expander").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})}),document.querySelectorAll(".category-name").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})})})</script><script src="/js/scroll-buttons.js?v=1753303881"></script></body></html>